The Use of the Hormones in Dermatology1

THE USE OF THE HORMONES IN DERMATOLOGY' MILTON M. IIAIITMAN, M.D., F.A.C.A. San Francisco, California

T he endocrine glands exert far reaching effects that we are only now beginning

to understand. Aside from the direct specific effects of the various endocrinopathies on the skin, there may be effects mediated through the autonomic nervous system. Endocrine dysfunction may affect the emotional state and aggravate or initiate psycho-somatic disorders. Allergic disturbances, in eluding

those of the skin, comprise an important group of ailments. That specific sensitivities arc not the complete answer to the etiology of allergic disorders, and that the approach by many of them is not the invariable answer to their treatment has long been known. Why a given allergen can at one time provoke

a clinical manifestation of allergy and at other times not, is determined by factors which modify the allergic status. Endocrine dysfunctions are among the important factors modifying this status. It is obvious that some knowledge of endocrinology is a necessity to the dermatologist wishing to arm himself \vith the maximum in effective therapeutic

weapons. A summary of the clinical and experimental uses of hormones in dermatology is herein presented under three logical headings: A. 5KIN DISORDERS DUE TO THR DEFIC1RNCY OR ABSENCR OF A SPRCIFIC ENDOCRINE PRODUCT RRSPONDING TO SUBSTITUTIVE THERAPY

rihe following phenomena should be matters of common knowledge: 1) The brownish pigmentation of adreno-cortieal deficiency (Addison's disease) being arrested and even reversed by adrenal cortex extracts and the synthetic desoxycorticosterone acetate. 2) The myxedema of hypothyroidism being fully corrected by dessicated thyroid or thyroxin. 3) The urticaria and dermographia of dystrophia adiposogenitalis, Froelieh's syndrome of anterior pituitary deficiency, responding to either pituitary or chorionic gonadotropin, but better to the combination. 4) The gradual disappearance of the lesions of xanthoma diabeticorum with insulin, a high-carbohydrate, low animal-fat diet, and thyroid,

if the basal metabolism is low. 5) The itching of pruritus vulvae of the climacteric and the atrophic changes of senile vaginitis being abolished by estrogens.

The component of kraurosis vulvae due to estrogen deficiency also responds, leaving only the degenerative inflammatory portion to combat. 6) The skin manifestations of ordinary diabetes mellitus responding to insulin, carbohydrate restriction, or both. 'Read before the Seventh Annual Meeting of the Society for Investigative Dermatology, San Francisco, California, June 30, 1946. (Presented by invitation.) Received for publication June 30, 1946. 229

230

THE JOURNAL OF INVESTIGATIVE DERMATOLOGY

Less well known but certainly not uncommon is so-called "skin diabetes", which Urbach has described under the name "independent cutaneous glycohistechia" (1). Urbach, for whom the disorder should really be named because of his brilliant investigational work, has used microchemical methods to show that the skin sugar may be significantly raised, even when the urine is negative and the fasting blood sugar is normal. According to Urbach's findings, the average skin sugar could be shown to be 58 mg. per 100 grams and abnormal values to be above 68 mg. per 100 grams. In Urbach's results, the average ratio between skin sugar and blood sugar was 61 per cent. When the ratio is 70 per cent or more one is justified in speaking of "independent cutaneous glycohistechia". According to Urbach, the skin lesions, most apt to occur in elderly, obese individuals with a purplish-red complexion, clear promptly on carbohydrate restriction, insulin administration, or both. Usually restriction is sufficient. If [Jrbach's results are confirmed, many of the therapy-resistant cases that dermatologists have cleared empirically by carbohydrate restriction have probably been Urbach's disease. The term chloasma is used to cover many types of pigmentary disturbances. Two of these, the common chloasma gravidarum and the less common menopausal chloasma, are due to estrogen excess and estrogen deficiency respectively. The hyperpigmentation of pregnancy is caused by the direct stimulation of the melanoblast cells by the high estrogen concentrations characteristic of pregnancy and is always limited to areas naturally containing pigment, such as the nipples,

areola, linen alba and face. Hyperpigmentation of the menopause may affect other areas, arid signs of skin senescence are present. The author noted clearing of the lesions in 12 of 17 menopausal patients under estrogen therapy and has never seen such pigmentation develop in the menopausal group as a result of such therapy. The fact that young women with amenorrhoea due to estrogen deficiency and lack of pigmentation will develop normal pigment as a result of estrogen therapy (2) shows that there must be a difference in pigmenting proces-

ses in the two age groups. B. SKiN DISORDERS NOT DUE TO A SPECIFIC HORMONE DEFICIENCY, BUT IN WHICH A HORMONE HAS A SPECIFIC USEFUL EFFECT

Urticaria and angioneurotic edema are helped temporarily by vasoconstrictors, the two most effective beillg epinephrine from the adrenal medulla and the pitressin from the posterior portion of the pituitary gland. The action of epinephrine

is the more rapid but the central stimulation is a disadvantage. Although not as intense initially, the action of pitressin is more prolonged. Experienced clinicians usually find it advantageous to combine them. In serum sickness the virtues of this combination are even more evident. The discovery that insulin exerts a beneficial effect in urticaria was made during investigations of serum potassium levels in allergic states (3). The serum potassium in normal individuals averages 19.5 mg. per 100 cc., ranging from 17.9 to 20.6. In acute and chronic urticaria the range is from 22 to 25.3 mg.

HORMONES IN DERMATOLOGY

231

per 100 cc., with an average of 23.4. Apparently the serum potassium increases

at the expense of the tissue cell potassium; the loss of potassium by the latter may be a significant factor. The administration of insulin, epinephrine parenterally, or dextrose intravenously bring about simultaneous relief of symptoms and a drop in the serum potassium level. Insulin plus dextrose administration

is more effective than either alone. Quite significantly, none of the cases in whom this beneficial effect of insulin has been observed has been a diabetic. Papular urticaria not only differs from the ordinary variety in appearance, out also in its response to maintained high serum calcium levels. Parathyroid hormone here serves a useful purpose in cutting down the frequency of injections

of calcium salts or doing away with such injections entirely. Parathyroid hormone is not meant to be used indefinitely, however, as people with this disorder almost invariably have serum calciums within the normal range. It is difficult to see why a majority of cases of herpes zoster should be symptomatically relieved by injections of pitressin. If the cutaneous lesions of herpes

zoster are due to the liberation of H-substance from the epidermal cells by antidromic impulses from the inflamed posterior root ganglion, epinephrine should also be effective. The author tried the effect of each, given separately in 18 cases of herpes zoster. Fourteen of these cases claimed relief of symptoms from the pitressin and only 2, both more relieved by pitressin, from epinephrine. Next came a group of unrelated disorders more or less aided by dessicated thyroid because of certain of its non-specific physiologic effects: the minority of xanthoma tuberosum cases respond because of the more rapid utilization of

fat incident to the raised metabolic rate. A majority of xeroderma cases and a minority of the more severe, and usually congenital iehthyosis simplex cases make some improvement because of the increased sweat and sebaceous gland activity and more rapid epidermal regeneration. Seborrheie dermatitis shows some improvement, but only if the pre-treatment basal metabolism is lower than average; disordered fat metabolism is probably to blame. Though most often these skin findings have no relation to a pituitary disease,

demonstrable transient mottling, purpuric spots, dark brown patches on the legs, hirsutism and symmetrical purplish striae over the axillary folds and popliteal spaces and trunk form a part of Cushing's syndrome. This syndrome is due either to primary adreno-cortical overactivity or overactivity secondary to a basophilic adenoma of the pituitary. For the primary type only the surgical

removal of the diseased adrenal is of avail. When pituitary basophilism is the cause, estrogen therapy to inhibit the hyperactive basophile cells has been successfully used (4). Gonorrheal vulvovaginitis before puberty presents a special problem because the immature vaginal mucosa is particularly susceptible to bacterial invasion. Temporary elevation of the epithelial cells to maturity by estrogen therapy, with a resulting thickening of the membrane, increase in the glycogen content of the epithelial cells, production of lactic acid and more acid pH (5), permits more

rapid control of the infection and prevents recurrences. Gonococci do not

232

THE JOURNAL OF INVESTIGATIVE DERMATOLOGY

thrive in a pH below 6. The route employed may be intramuscular, oral or vaginal, the last being preferable. Even the most ferveilt advocates of sulfonamide and penicillin therapy admit the advisability, if not the necessity, of a short period of estrogen therapy in this group. Gonorrhea after the menopause may similarly require estrogen for its more rapid or permanent eradicatioii. Trichomonas vulvovaginitis in the menopausal and post-menopausal periods

offers a comparable problem with the above. Here we are dealing with an infection on an epithelial surface going through atrophic changes and the net effect is the same as underdevelopment, namely, lowered resistance to infection

and neutral or alkaline reaction. The protozoan nature of the invader denies the ailing female the spectacular effects of the sulfonamides and penicillin, and treatment takes the form of local use of such preparations as silver picrate, vioform, carbarsone, etc. Whatever therapy is used, it is the universal experience of the gynecologist or dermatologist that it takes at least two or three times longer to cure the ailment after the menopause than before it. If adequate estrogen is administered concommitantly with the usual local therapy, however, the latter group takes no longer to clear up than the former.

Mention has been made of chloasma after the menopause responding to estrogen therapy. The more common chloasma of pregnancy, chloasma gravidarum, presented the opposite problem, that of neutralizing the excessive

estrogen of pregnancy or diminishing its rate of formation. Although the action of estrogens on the melanoblast cells is a direct one, evidence points to normal anterior pituitary function as being a necessity (2). The author reasoned that the cautious administration of androgen might (a) neutralize the estrogen, (b) diminish anterior pituitary secretory activity, or (c) diminish the anterior

pituitary stimulation of estrogen production by the ovaries, the ehoriome source remaining uninfluenced. Such experimentation necessarily had to be exceedingly cautious and only in cases that were advancing so rapidly that they were being grossly disfigured or becoming psychiatric problems. Of 18 such

cases, 9 were kept as controls and 9 treated with methyl testosterone orally. Dosage employed was 10 mg. once or twice daily for 2 to 4 weeks, and a total

of 300 mg. was never exceeded. The results were gratifying: in 7 of the 9 treated cases the progress of the skin lesions was promptly arrested, and the rate

of regression of the lesions was much faster than in the control group. No effect on either the offspring or the course of labor was noted. C. SKIN DISORDERS iN WHICH ENDOCRINE MALFUNCTION MAY BE A PRECIPITATING OR AGGRAVATING FACTOR

This group includes atopic dermatitis, which is usually of allergic origin, urticaria, which often is, and acne vulgaris or juvenilis, which only infrequently

is. A minority of cases of each gives the impression of thyroid or gonadal malfunction. The following chart summarizing the author's experiences with thyroid medication of atopic dermatitis, urticaria and acne is presented:

233

HORMONES IN DERMATOLOGY

BAS1L MET%BOLISI RANGE

Atopic dermatitis: Ages

Above +20%

None

ranging from 9 to 47— 67 eases

+20 to +10

3 48 7 6 3

+10 to —10 —lOto—20 —2Oto—25 Below —25

Totals

tJrticaria: Ages ranging from 10 to 61—61 Cases

67

Above +20%

None

+20 to +10 —10 tC) —20

7 41 9

Below —20

4 61

+10 to —10

Totals Acne vulgaris: ages rang-

Above +20%

ing from 13 to 32—62

+20 to +10

cases

+10 to —10 —10 to —20 Below —20

Totals

CASES TREATED WITH THYROID

CASES BENEFITED BY THYROID

None None

— —

25 7

3

3

5 5 3

41

16

6

— None 32

—..

9

4

4 2

45

0

——

3

2

None

7 41 9 3

None

—

30 9

10 7

3

2

62

42

10

The data permit a few conclusions to be drawn: 1. In atopic dermatitis and urticarias abnormally high basal metabolic rates were not encountered. 2. In atopie dermatitis and urticarias there were significantly more cases below the normal range of +10 per cent to —10 per cent than above. This was most notable with atopic dermatitis. 3. The acne group was fairly symmetrically divided in the percentage brackets. 4. In all three categories the per cent benefitted from thyroid administration

was proportionate to the need, as indicated by the basal metabolic rates. 5. TJrticaria was the least benefitted, 9 out of 45 (20 per cent), and acne the most, 19 out of 42 (45 per cent). In atopic dermatitis, benefit was intermediate, with 16 out of 41 (39 per cent). The female patient from puberty to menopause presents a constantly changing

sex hormone picture. Oniy before the upheaval of puberty and after the menopausal decline can she be considered endocrinologically static. Even the hormonal fluctuations of the menstrual cycles during the period of sexual maturity

are altered by incidental pregnancies. It therefore behooves the therapist to first correlate the onset, exacerbation or disappearance of the skin lesions with the events of the menstrual cycle, pregnancy, puberty, or the climacteric. To this end a short resumé of pituitary and ovarian function is in order: In childhood the blood concentration of estrogen (female sex hormone) is

234

THE JOURNAL OF INVESTiGATIVE DERMATOLOGY

low and relatively constant. Under the influence of the anterior pituitary follicle stimulating hormone (FSII) (Thylakentrin) at puberty the ovary produces estrogens which in turn promote the secondary sex characteristics. Menstrual

cycles then put in their appearance. At the time of menstruation estrogen is at its lowest level. Thylakentrin then stimulates a primordial follicle to grow and the ovary in general, but the follicle in particular to produce estrogen. Blood estrogen levels increase until ovulation, when there is a sudden drop (after which there may be slight intermenstrual bleeding), followed by a second

and higher peak at about the twenty-second day of the cycle. There is an accompanying peak of progesterone, which has been produced from the corpus luteum since ovulation in increasing amounts, along with estrogen under the stimulation of the anterior pituitary luteinizing hormone (LII) (Tvletakentrin). The concentration of both then drops, particularly rapidly at about the twentysixth day, to their lowest levels of the cycle, during menstruation and the few

days following. There is an interesting reciprocal relationship, as the rising estrogen concentration inhibits the production or release of the anterior pituitary sex hormones (6, 9). Cyclic uterine bleeding, whether ovulatory or anovulatory, is due essentially to a preceding drop in the blood estrogen level, allowing en-

dometrial regression and degeneration (7). At the climacteric the ovary is no longer effectively responsive to pituitary stimulation, estrogen is not produced

in sufficient quantity to inhibit the pituitary, and the familiar menopausal symptoms result, presumably because of the presence of excess anterior pituitary

sex hormones, particularly Thylakentrin (8). The administration of estrogen, preferably, but even androgen, can relieve these symptoms by inhibiting the anterior pituitary. Rare cases of urticaria related to puberty are transient, and the result of the emotional state, hence better controlled by psychotherapy than hormones. Menopausal urtiearias, resulting from dysfunction of the vasomotor mechanisms

are controlled by the administration of estrogen in the majority of eases (85 per cent in the author's series). With the restoration of the normal pituitaryovarian hormone relationship, the urtiearial difficulties end with the others. The therapist then allows a gradual transition to the post-menopausal state instead of a sudden one to prevent recurrences. Premenstrual urtiearia and menstrual urticaria are fundamentally different in etiology and it is important to distinguish between them, as their treatment differs radically. Menstrual urtiearia does not make its appearance until the day before men-

struation at the earliest, but usually on the first day. There is ordinarily more or less nervousness, irritability, dysmenorrhea, and abnormality of flow; little or no fever is the rule. Simple sedatives may work wonders but the physiological preventative is an injection of estrogen, preferably one of the estradiol or "natural" series so times as to give an optimum concentration when needed.

Dose and timing vary with the patient. It usually requires a dose of 1 to 2

milligrams of alpha-estradiol dipropionate or benzoate given 2 to 4 days before the onset of the period. Of 19 such eases, theintramuscularly author has had

HORMONES IN DERMATOLOGY

235

unsatisfactory results in only 2; the rest enjoyed complete prevention of the urti-

caria or marked minimization. The dysmenorrhea, when present, was not consistently affected. Premenstrual urticaria is associated with premenstrual tension, classically including nausea, headache, fever, nervous tension and lower abdominal and

back pains. The symptoms are present for from 5 to 7 days before the onset of the period and end as menstruation begins. These patients suffer from too much estrogen (10, 11); the post-ovulatory or premenstrual blood estrogen concentration rises to a height which gives toxic manifestations, or, as Zondek's report suggests, they are allergic to their own endocrine products (12). When this latter group is tested intradermally with estradiol or estrone in oil (0.1 nig. in 0.1 cc. oil) with a simultaneous oil control a positive skin test is obtained.

It is either papular or erythematous, usually coming on in 3 to 5 hours and persisting at least a day. A passive transfer of their premenstrual serum to normal women will give positive tests with estradiol, but the normal recipient's

untreated site will not react to estradiol. In the menstrual urticaria group neither the direct nor the passive transfer test can be elicited. Two types of treatment are available in the premenstrual group. The first that the author has used successfully is the administration of 10 milligrams of methyl testosterone

orally twice daily for 10 days before the expected period. This depresses the anterior pituitary function, which, in turn, results in less production of estrogen by the ovary; a direct antagonism of androgen and estrogen is also a possibility (13). Of 12 cases treated in this manner, 11 responded satisfactorily. The second treatment is subcutaneous or intramuscular desensitization to alphaestradiol, starting with the amount just failing to give a positive skin test. The succeeding doses are given every 2 or 3 days; 7 out of 10 cases treated in this way gave an excellent response. It is of interest to note that urticarial attacks occurring in the premenstrual period can be duplicated in the intermenstruum by injecting serum taken during the pre-menstrual period (14). TJrtiearia in the male offers no comparable problems except in the elimacterie and sex hormone treatment is rarely justified or indicated. The male elimacterie is occasionally accompanied by urtiearia and generalized itching without visible lesions is not uncommon. The response to substitutive therapy with androgens

is good. Acne and eczema in the male, before we discuss these disorders in the female, are best left alone from the sex hormone standpoint. In our present state of knowledge we can do no good to the male's acne or atopic dermatitis, and we could conceivably harm his pituitary-gonadal equipment. Acne and atopie dermatitis in the female offer comparable, but not as clearcut features as urtiearia in the female. One gets the impression that there are

menstrual and premenstrual types, but the persistence of the lesions makes distinctions difficult. The menstrual type has given only fair response to estrogen treatment; indeed, the advisability of such therapy in the young female, for the most part inconclusive in results, is debatable. In 2 of 6 "premenstrual

aenes" oral methyl testosterone therapy gave fair results; the other results were equivocal. Desensitization with their own blood serum taken during the

236

THE JOURNAL OF INVESTIGATIVE DERMATOLOGY

premenstrual phase (15) gave good results in 3 such acne cases and failures in 4. Four out of 5 "premenstrual acnes" giving positive estrogen skin tests benefitted

by estradiol desensitization therapy. In general, the author cannot help but feel that sex hormone therapy in this group is rarely indicated. The treatment of asymptomatic skin senescence by sex hormones belongs in the business of cosmetology rather than the practice of medicine. The process of aging has more than its hormonal aspects. While it is true that the topical application or internal administration of estrogen in the female and androgen in the male can make perceptible changes in the appearance and texture of the skin, the effects are temporary and never fully corrective. It is questionable whether the results attained are worth the risks involved in the necessarily prolonged treatment. In experimental animals prolonged high estrogen therapy results in pituitary changes, the basophile cells becoming completely degranulated the acidophiles almost totally degranulated, and large chromophobic adenomata

forming. Uncontrolled androgen therapy can lead to prostatic hypertrophy and neoplasm in susceptible men. Topical application of estrogens along with unpredictable absorption has the potential danger of carcinogenesis. Although the small dosage usually used in topical applications has never been shown to produce tumors and must therefore at present be considered "safe", protracted estrogen stimulation by any route, plays a part in the growth of uterine fibroids (16, 17), endometriomata (18), and cervical neoplasms (19). The incidence of carcinoma of the breast also is believed to be increased by prolonged estrogen stimulation (20, 21). REFERENCES (1) URBACH, E.: Skin diabetes: hyperglycodermia without hyperglycemia .J.A. M. A., 129: 438 (Oct. 6) 1945. (2) DAvis, M. EDWARD, BoyxTox, M. W., FERGUSON, J. H., AND ROTHMAN, S.: Studies

on pigmentation of endocrine origin. J. Endocrinol., 5: 138 (March) 1945. (3) Rusic, H. A., WEICHSELBAUM, T. E., Soxuoovm, M., AND Sianis, M.: Changes in serum

potassium in certain allergic states. J. A. M. A., 112: 2395 (June 10) 1939. (4) RAKOFF, A. E., CANTAROW, A., AND PosduKIs, K. E.: Cushing's syndrome. Two cases

treated with stilbestrol. J. Clin. Endocrinol., 1: 912, 1941.

(5) LEWIs, H. M., ANn ADLER, E. L.: Endocrine treatment of vaginitis of children and of

women after the menopause. J. A. M. A., 109: 1873 (Dcc. 4) 1937. (6) L0TILA, U. U.: The effect of estrin on the anterior pituitary of male rats after pituitary stalk section. Endocrinol., 26: 123, 1940. (7) MARKER, J. E., AND BERG, B.: Cyclic fluctuations in blood estrogen as a possible cause

of menstruation. Stanford Medical Bulletin, 2: 55 (May) 1944. (8) FLUIIMANN, C. F.: Menstrual Disorders. W. B. Saunders Co., Phila. Pa., 1939, p.301. (9) MOORE, C. H., AND PRICE, D.: Gonad hormone functions, and the reciprocal influences

between gonads and hypophysis with its bearing on the problem of sex hormone antagonism. Am. J. Anat., 50: 13, 1932. (10) FRANK, H. T.: The hormonal causes of premenstrual tension. Arch. Neurol. & Pschychiat., 26: 1053 (Nov.) 1931. (11) ISKAEL, S. L.: Premenstrual tension. J. A. M. A., 110: 1721 (May 21) 1938. (12) ZoNnEK, B., AND BEOMBEEG, Y. M.: Endocrine allergy. Allergic sensitivity to endogenous hormones. J. Allergy, 16: 1 (Jan.) 1945.

HORMONES IN DERMATOLOGY (13)

237

Snona, E., PAPANICALOTI, C. N., AND STIMMEL, B. F.: Neutralization of ovarian follicular hormone in women fly simultaneous administration of male sex hormone. Proc. Soc. Exper. Biol. & Med., 38: 759 (June) 1938.

(14) CEDER, J.: Desensitization in the treatment of menstrual intoxication and other allergic symptoms. British J. Dermnt., 51: 265, 1939. (15) URBACFI, E.: Menstruation allergy. International Clinics, 2: 160, 1939. (16) WITilEascooN, J. T.: The hormonal origin of uterine fibreids: an hypothesis. Am. J. Cancer, 24: 402, 1935.

(17) LIPscauTz, A.: Experimentnl fihreids and the nntifibromatogenic action of the steroid hormones .J.A. M .A., 120: 171, 1942. (18) LAcAS5AGNE, A.: Modifications progresives de l'uterus de la souris sous l'action prolongde de l'oestrone. Comt. Rend. Sec. de Bid., 120: 1156, 1935. (19) CAItDNER, W. U., ALLEN, E., SMITH, C. M., AND STRONG, L. C.: Carcinoma of the cervix of mice receiving estrogens .J.A. M A., 110: 1182, 1938. (20) 1iEraEaG, B., AND HEInaae, P.: Some investigations into the occurrence of carcinoma of the hreast with special reference to the ovarian function .Acta Clur. Scnndinav., 83: 479, 1940. (21) JIERRELL, W. E.:

The relative incidence of oephorectemy in women with and without carcinoma of the breast. Am. J. Cancer, 29: 659, 1937.

THE JOURNAL OF INVESTIGATIVE DERMATOLOGY

94

linolenic acid extract. Arch. This pdf is a scanned copy UV of irradiated a printed document.

24. Wynn, C. H. and Iqbal, M.: Isolation of rat

skin lysosomes and a comparison with liver Path., 80: 91, 1965. and spleen lysosomes. Biochem. J., 98: lOP, 37. Nicolaides, N.: Lipids, membranes, and the 1966.

human epidermis, p. 511, The Epidermis

Eds., Montagna, W. and Lobitz, W. C. Acascopic localization of acid phosphatase in demic Press, New York. human epidermis. J. Invest. Derm., 46: 431, 38. Wills, E. D. and Wilkinson, A. E.: Release of 1966. enzymes from lysosomes by irradiation and 26. Rowden, C.: Ultrastructural studies of kerathe relation of lipid peroxide formation to tinized epithelia of the mouse. I. Combined enzyme release. Biochem. J., 99: 657, 1966. electron microscope and cytochemical study 39. Lane, N. I. and Novikoff, A. B.: Effects of of lysosomes in mouse epidermis and esoarginine deprivation, ultraviolet radiation and X-radiation on cultured KB cells. J. phageal epithelium. J. Invest. Derm., 49: 181, 25. Olson, R. L. and Nordquist, R. E.: Ultramicro-

No warranty is given about the accuracy of the copy.

Users should refer to the original published dermal cells. Nature, 216: 1031, 1967. version of1965. the material. vest. Derm., 45: 448, 28. Hall, J. H., Smith, J. G., Jr. and Burnett, S. 41. Daniels, F., Jr. and Johnson, B. E.: In prepa1967.

Cell Biol., 27: 603, 1965.

27. Prose, P. H., Sedlis, E. and Bigelow, M.: The 40. Fukuyama, K., Epstein, W. L. and Epstein, demonstration of lysosomes in the diseased J. H.: Effect of ultraviolet light on RNA skin of infants with infantile eczema. J. Inand protein synthesis in differentiated epi-

C.: The lysosome in contact dermatitis: A ration. histochemical study. J. Invest. Derm., 49: 42. Ito, M.: Histochemical investigations of Unna's oxygen and reduction areas by means of 590, 1967. 29. Pearse, A. C. E.: p. 882, Histochemistry Theoultraviolet irradiation, Studies on Melanin, retical and Applied, 2nd ed., Churchill, London, 1960.

30. Pearse, A. C. E.: p. 910, Histacheini.stry Thearetscal and Applied, 2nd ed., Churchill, London, 1960.

31. Daniels, F., Jr., Brophy, D. and Lobitz, W. C.: Histochemical responses of human skin fol-

lowing ultraviolet irradiation. J. Invest. Derm.,37: 351, 1961.

32. Bitensky, L.: The demonstration of lysosomes by the controlled temperature freezing section method. Quart. J. Micr. Sci., 103: 205, 1952.

33. Diengdoh, J. V.: The demonstration of lysosomes in mouse skin. Quart. J. Micr. Sci., 105: 73, 1964.

34. Jarret, A., Spearman, R. I. C. and Hardy, J. A.:

Tohoku, J. Exp. Med., 65: Supplement V, 10, 1957.

43. Bitcnsky, L.: Lysosomes in normal and pathological cells, pp. 362—375, Lysasames Eds., de Reuck, A. V. S. and Cameron, M. Churchill, London, 1953.

44. Janoff, A. and Zweifach, B. W.: Production of inflammatory changes in the microcirculation by cationic proteins extracted from lysosomes. J. Exp. Med., 120: 747, 1964.

45. Herion, J. C., Spitznagel, J. K., Walker, R. I. and Zeya, H. I.: Pyrogenicity of granulocyte lysosomes. Amer. J. Physiol., 211: 693, 1966.

46. Baden, H. P. and Pearlman, C.: The effect of ultraviolet light on protein and nucleic acid synthesis in the epidermis. J. Invest. Derm.,

Histochemistry of keratinization. Brit. J. 43: 71, 1964. Derm., 71: 277, 1959. 35. De Duve, C. and Wattiaux, R.: Functions of 47. Bullough, W. S. and Laurence, E. B.: Mitotic control by internal secretion: the role of lysosomes. Ann. Rev. Physiol., 28: 435, 1966. the chalone-adrenalin complex. Exp. Cell. 36. Waravdekar, V. S., Saclaw, L. D., Jones, W. A. and Kuhns, J. C.: Skin changes induced by

Res., 33: 176, 1964.